시장보고서

상품코드

1772254

미국의 분자생물학용 효소, 시약, 키트 시장 규모, 점유율, 동향 분석 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

U.S. Molecular Biology Enzymes, Reagents And Kits Market Size, Share & Trends Analysis Report By Product (Kit and Reagents, Enzymes), By Application (Cloning, NGS, PCR), By End Use, And Segment Forecasts, 2025 - 2033

발행일: 2025년 06월 | 리서치사:

Grand View Research | 페이지 정보: 영문 137 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

시장 규모와 동향 :

미국의 분자생물학용 효소·시약·키트 시장 규모는 2024년에 59억 5,000만 달러로 추계되며, 2025-2033년에 CAGR 9.65%로 성장할 것으로 예측됩니다.

미국 질병예방통제센터(CDC)에 따르면 클라미디아, 임질, 매독 등 성병은 지난 10년간 꾸준히 증가하여 최근 250만 건 이상의 사례가 보고되었습니다. 연구, 진단, 치료에서 분자 기술의 응용 확대.

미국암협회에 따르면 2024년 미국에서는 비뇨기 방광암을 제외한 기저세포 및 편평상피 피부암과 비침윤성 제자리 암을 제외한 200만 건 이상의 신규 암이 진단될 것으로 예측됩니다. 이러한 질병 부담 증가는 미국이 이 시장에서 리더십을 유지할 것으로 예측됩니다.

2024년 11월, 캘리포니아주 공중보건국(CDPH)은 미국 최초로 임상 검사를 통해 제1군 수두 환자를 확인했습니다. 이 환자는 최근 수두가 유행하는 지역을 여행한 적이 있는 환자로, PCR 검사를 통해 비변종 수두 바이러스가 확인되어 I형 수두로 확진되었습니다. I형 수두의 출현은 신속하고 정확한 분자진단의 필요성을 강조하고 차세대 PCR 및 시퀀싱 기술에 대한 투자를 촉진하고 있습니다.

이 시장에는 PCR, qPCR, RT-PCR, 클로닝, 시퀀싱, 유전자 발현 분석 등의 프로세스용으로 설계된 중합효소, 리가제, 뉴클레아제, 완충액, 특수 시약 키트 등 다양한 제품이 포함됩니다. 또한 엔테로바이러스는 5세 미만의 유아에게도 감염되며, 감염된 유아의 약 41%가 산소호흡기를 필요로 합니다. 또한 2021년 5월 미국 국립의학도서관이 발표한 논문에 따르면 미국에서는 매년 인구의 약 40%가 헬리코박터 파일로리균 감염의 영향을 받고 있습니다.

승인 및 자금 지원의 형태로 정부 지원의 존재는 예측 기간 중 시장 성장을 가속할 것으로 예측됩니다. 예를 들어 2022년 5월 Abbott는 미국 FDA로부터 Alinity m STI Assay를 승인받았습니다. 이 검사는 STI를 감별하고 검출할 수 있습니다. 또한 2020년에는 ASPR의 Biomedical Advanced Research and Development Authority와 NIH의 National Institute of Allergy and Infectious Diseases가 Antimicrobial Resistance Diagnostic Challenge를 개최하여 Visby Medical의 신속 PCR 검사가 1,900만 달러의 연방 자금을 획득했습니다.

또한 2022년 9월, 레드버드 메디신은 시리즈 A에서 1,000만 달러의 자금을 조달했습니다. 연방 정부의 자금 지원은 지역 및 주정부 검사 기관의 역량을 강화하여 수요 증가에 대응할 수 있도록 돕습니다. 마찬가지로 2023년 6월, Accelerate Diagnostics는 Wave 플랫폼과 새로운 신속 검사 개발을 가속화하기 위해 2,400만 달러를 지원받았습니다. 감염증의 다양성과 원인균의 내성화로 인해 감염증의 분자진단 검사 메뉴는 고정적이고 피상적인 것으로는 허용되지 않습니다.

또한 프로메가 코퍼레이션(Promega Corporation), 써모 피셔 사이언티픽(Thermo Fisher Scientific) 등 비용 효율적이고 고품질의 진단용 효소를 광범위하게 제공하는 주요 기업이 미국에 진출해 있는 것도 미국 시장을 촉진하고 있습니다. 이들 기업은 바이오센서, 당뇨 측정기, POC(Point-Of-Care) 기기, 간, 심혈관, 신장 및 기타 질환의 체외 진단에 사용할 수 있는 효소를 제공합니다. 2024년 9월, 프로메가는 법의학 DNA 분석에서 말더듬이를 줄이는 새로운 효소 변종을 발표하며 중합효소 키트의 혁신성을 강조했습니다. 한편, qPCR과 RT-PCR 키트는 PCR 시스템 업그레이드와 하이스루풋 랩의 도입에 힘입어 호조세를 유지하고 있습니다. 또한 2021년 2월 애질런트 테크놀러지는 Agilent Dako SARS-CoV-2 IgG 효소 결합 면역 흡착 측정 키트를 출시했습니다. 이 키트는 인간 혈청 또는 혈장내 SARS-CoV-2에 대한 IgG 항체를 검출합니다.

진단 분석에 사용되는 주요 시약에는 형광 태그, 세척 완충액, 특이 항체, 면역화학 검사를 위한 단백질 바이오마커, PCR 검사를 위한 dNTP 및 프라이머 믹스 등의 필수 화학물질이 포함됩니다. 분자진단에서는 형광 표지 뉴클레오티드와 프라이머가 특히 Abbott, Illumina, Roche Diagnostics와 같은 업계 선두 업체에서 자주 활용되고 있습니다.

COVID-19 관련 시약에 대한 규제 당국의 승인도 시장에 활력을 불어넣고 있습니다. 미국 FDA는 2021년 3월 BioFire Respiratory Panel 2.1을 510(k) 승인을 통해 COVID-19를 포함한 여러 호흡기 감염증을 검출할 수 있도록 했습니다. 마찬가지로 2020년 4월 Ortho Clinical Diagnostics는 VITROS 진단 시스템에서 작동하는 VITROS Immunodiagnostic Anti-SARS-CoV-2 Total Reagent Pack and Calibrators에 대한 긴급사용승인(EUA)을 획득했습니다. (EUA)를 획득했습니다. 이번 승인으로 의료 전문가들은 COVID-19 팬데믹 초기에 발생한 일시적인 공급 부족 상황에서도 COVID-19를 더 잘 관리하고 예방할 수 있게 되었습니다. 이러한 공급 부족은 정부의 개입, 공급망 복구 및 대체 제품 출시로 인해 결국 완화되었습니다.

시장 점유율 : 용도별(2024년·2033년)
부문 대시보드
세계의 분자생물학용 효소·시약·키트 시장의 전망 : 용도별
시장 규모 예측과 동향 분석(2021-2033년)
- 클론
- 시퀀싱
- PCR
- 에피제네틱스
- 유전자형 판정
- RCA/MDA
- RNA 세라퓨틱스
- 전사체학
- 단백질체학
- 액체생검
- 기타 용도

제6장 분자생물학용 효소·시약·키트 시장 : 최종 용도별 추정·동향 분석

시장 점유율 : 최종 용도별(2024년·2033년)
부문 대시보드
세계의 분자생물학용 효소·시약·키트 시장의 전망 : 최종 용도별
시장 규모 예측과 동향 분석(2021-2033년)
- 제약·바이오테크놀러지
- 학술연구
- 병원·진단
- 기타

제7장 경쟁 구도

최신 동향과 영향 분석 : 주요 시장 참여 기업별
기업 분류
기업 히트맵 분석
기업 개요
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- QIAGEN
- Promega Corporation
- New England Biolabs
- Merck KGaA
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Takara Bio, Inc.
- LGC Limited

KSA

Market Size & Trends:

The U.S. molecular biology enzymes, reagents and kits market size was estimated at USD 5.95 billion in 2024 and is projected to grow at a CAGR of 9.65% from 2025 to 2033. The market is driven by growing burden of chronic diseases and infectious diseases such as sexually transmitted diseases (STDs) across the U.S. According to the Centers for Disease Control and Prevention (CDC), STDs such as chlamydia, gonorrhea, and syphilis have been increasing steadily over the past decade, with over 2.5 million cases reported in recent years. The expanding application of molecular technologies in research, diagnostics, and therapeutics.

According to the American Cancer Society, over 2 million new cancer cases are projected to be diagnosed in the U.S. in 2024, excluding basal and squamous cell skin cancers and noninvasive carcinoma in situ, except for urinary bladder cases. This rising disease burden is expected to sustain the country's leadership in the market.

In November 2024, the California Department of Public Health (CDPH) confirmed the first case of clade I mpox in the U.S. through laboratory testing. The diagnosis was made in a patient who had recently traveled to an outbreak region. PCR testing identified non-variola orthopoxvirus and confirmed clade I mpox, with further analysis conducted by the CDC. The emergence of clade I mpox underscores the necessity for rapid and precise molecular diagnostics, fostering investment in next-generation PCR and sequencing technologies.

This market encompasses a broad range of products, including polymerases, ligases, nucleases, buffers, and specialized reagent kits designed for processes such as PCR, qPCR, RT-PCR, cloning, sequencing, and gene expression analysis. Furthermore, enterovirus also majorly affects the population with ages less than 5 years, of which around 41% of the infected toddlers require supplemental oxygen. In addition, according to the article published by the National Library of Medicine in May 2021, around 40 % of the U.S. population in the U.S. is affected by H. pylori infection every year.

The presence of government support in the form of approvals and funding is anticipated to fuel the market growth over the forecast period. For instance, in May 2022, Abbot received approval for its Alinity m STI Assay from the U.S. FDA. The test is capable of differentiating and detecting STIs. In addition, in 2020, ASPR's Biomedical Advanced Research and Development Authority and NIH's National Institute of Allergy and Infectious Diseases organized the Antimicrobial Resistance Diagnostic Challenge in which Visby Medical's rapid PCR test won USD 19 million in federal funding.

In addition, in September 2022, Redbud Medicine raised USD 10 million in Series A funding. Federal funding also helps local and state laboratories increase their capacity and allows them to keep up with increasing demand. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of the Wave platform and novel rapid testing. Molecular diagnostics test menus for infectious diseases cannot afford to be static or superficial due to the diverse nature of infectious diseases and the building resistance of causative agents.

Furthermore, local presence of key players such as Promega Corporation and Thermo Fisher Scientific, which offer cost-effective, high-quality, & a wide range of enzymes to be used in diagnosis, is driving the U.S. market. These companies offer enzymes that can be used in biosensors, diabetes meters, point-of-care devices, and in vitro diagnosis of liver, cardiovascular, renal, and other disorders. Promega introduced a novel enzyme variant in September 2024 that cuts stutter in forensic DNA analysis, highlighting innovation in polymerase kits. Meanwhile, qPCR and RT-PCR kits remain strong, supported by PCR system upgrades and high-throughput lab adoption. In addition, in February 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG enzyme-linked immunosorbent assay kit. It detects IgG antibodies to SARS-CoV-2 in human blood serum or plasma.

Key reagents used in diagnostic assays include fluorescent tags, washing buffers, specific antibodies, and protein biomarkers for immunochemistry tests, along with essential chemicals like dNTP and primer mixes for PCR testing. In molecular diagnostics, fluorescent-labeled nucleotides and primers are frequently utilized, particularly by industry leaders such as Abbott, Illumina, Inc., and Roche Diagnostics.

Regulatory approvals for COVID-19-related reagents have also fueled the market. The U.S. FDA granted 510(k) clearance for the BioFire Respiratory Panel 2.1 in March 2021, enabling the detection of multiple respiratory infections, including COVID-19. Similarly, in April 2020, Ortho Clinical Diagnostics received an Emergency Use Authorization (EUA) for the VITROS Immunodiagnostic Anti-SARS-CoV-2 Total Reagent Pack and Calibrators, which operate on the VITROS diagnostic systems. Such approvals allow healthcare professionals to better manage and prevent COVID-19, even amidst temporary shortages that occurred early in the pandemic. These shortages were eventually mitigated through governmental interventions, restored supply chains, and the launch of alternative products

U.S. Molecular Biology Enzymes, Reagents And Kits Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. molecular biology enzymes, reagents and kits market report based on product, application, and end use

Product Outlook (Revenue, USD Million, 2021 - 2033)

Kits & Reagents
PCR Kits
qPCR Kits
RT-PCR Kits
Library Preparation Kits
Cloning Kits
Purification Kits
Gene Editing Kits
Other Kits
Enzymes
Polymerases
- DNA Polymerases
- High Fidelity DNA Polymerases
- Pfu DNA Polymerases
- Phusion DNA Polymerases
- Hot Start DNA Polymerases
- Taq DNA Polymerases High Fidelity
- Others
- Thermostable DNA Polymerases
- Standard Taq DNA Polymerases
- Tth DNA Polymerases
- Others
- Strand-displacing DNA Polymerases
- Bst DNA Polymerases
- Phi29 DNA Polymerases
- Others
- RNA Polymerases
- T7 RNA Polymerase
- SP6 RNA Polymerase
- T3 RNA Polymerase
- Other RNA Polymerase
Reverse Transcriptase (RTs)
- M-MLV RT
- AMV RT
- Thermostable RT
- Template Switch
- TGIRT
- Induro
- MarathonRT
Ligases
- DNA Ligases
- T4 DNA Ligases
- E coli DNA Ligase
- Taq DNA Ligase
- Others
- RNA Ligases
Nucleases
- DNase I
- RNase A, RNase H
- Nickases
- Restriction Nucleases
- TdTs
Endonucleases
- EndoQ
- AP Nuclease
Kinases
Phosphatases
CRISPR-associated Enzymes
- Cas9
- Cas12a (Cpf1)
- Cas13
Specialty Enzymes
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Cloning
Sequencing
PCR
Epigenetics
Genotyping
RCA/MDA
RNA Therapeutics
Transcriptomics
Proteomics
Liquid Biopsy
Other Applications
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharma & Biotech
- Research
- Therapeutics/Production
Academic & Research
Hospital & Diagnostics
Others

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Product Outlook
- 2.2.2. Application Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Molecular Biology Enzymes, Reagents And Kits Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Molecular Biology Enzymes, Reagents And Kits Market Analysis Tools
- 3.3.1. Industry Analysis Porter's
- 3.3.2. PESTEL Analysis

Chapter 4. Molecular Biology Enzymes, Reagents And Kits Market: Product Estimates & Trend Analysis

4.1. Product Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Global Molecular Biology Enzymes, Reagents And Kits Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 4.4.1. Kits & Reagents
  - 4.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.1.2. PCR Kits
    - 4.4.1.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.1.3. qPCR Kits
    - 4.4.1.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.1.4. RT-PCR Kits
    - 4.4.1.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.1.5. Library Preparation Kits
    - 4.4.1.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.1.6. Cloning Kits
    - 4.4.1.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.1.7. Purification Kits
    - 4.4.1.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.1.8. Gene Editing Kits
    - 4.4.1.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.1.9. Other Kits
    - 4.4.1.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 4.4.2. Enzymes
  - 4.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.2. Polymerases
    - 4.4.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.2.2. DNA Polymerases
      - 4.4.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.2.2.2. High Fidelity DNA Polymerases
        
        4.4.2.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        4.4.2.2.2.2.2. Pfu DNA Polymerases
  - 4.4.2.2.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.2.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.2.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.2.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.2.3. RNA Polymerases
      - 4.4.2.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.2.3.2. T7 RNA Polymerase
        
        4.4.2.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.2.3.3. SP6 RNA Polymerase
        
        4.4.2.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.2.3.4. T3 RNA Polymerase
        
        4.4.2.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.2.3.5. Other RNA Polymerase
        
        4.4.2.2.3.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.3. Reverse Transcriptase (RTs)
    - 4.4.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.3.2. M-MLV RT
      - 4.4.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.3.3. AMV RT
      - 4.4.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.3.4. Thermostable RT
      - 4.4.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.3.5. Template Switch
      - 4.4.2.3.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.3.6. TGIRT
      - 4.4.2.3.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.3.7. Induro
      - 4.4.2.3.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.3.8. MarathonRT
      - 4.4.2.3.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.4. Ligases
    - 4.4.2.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.4.2. DNA Ligases
      - 4.4.2.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.4.2.2. T4 DNA Ligases
      - 4.4.2.4.2.3. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.4.2.4. E coli DNA Ligase
      - 4.4.2.4.2.5. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.4.2.6. Taq DNA Ligase
      - 4.4.2.4.2.7. market estimates and forecasts 2021 to 2033 (USD Million)
      - 4.4.2.4.2.8. Others
      - 4.4.2.4.2.9. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.4.3. RNA Ligases
      - 4.4.2.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.5. Nucleases
    - 4.4.2.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.5.2. DNase I
      - 4.4.2.5.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.5.3. RNase A, RNase H
      - 4.4.2.5.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.5.4. Nickases
      - 4.4.2.5.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.5.5. Restriction Nucleases
      - 4.4.2.5.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.5.6. TdTs
      - 4.4.2.5.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.6. Endonucleases
    - 4.4.2.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.6.2. EndoQ
      - 4.4.2.6.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.6.3. AP Nuclease
      - 4.4.2.6.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.7. Kinases
    - 4.4.2.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.8. Phosphatases
    - 4.4.2.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.9. CRISPR-associated Enzymes
    - 4.4.2.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.9.2. Cas9
      - 4.4.2.9.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.9.3. Cas12a (Cpf1)
      - 4.4.2.9.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    - 4.4.2.9.4. Cas13
      - 4.4.2.9.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.10. Specialty Enzymes
    - 4.4.2.10.1. market estimates and forecasts 2021 to 2033 (USD Million)
  - 4.4.2.11. Others
    - 4.4.2.11.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Molecular Biology Enzymes, Reagents And Kits Market: Application Estimates & Trend Analysis

5.1. Application Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Global Molecular Biology Enzymes, Reagents And Kits Market by Application Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 5.4.1. Cloning
  - 5.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.2. Sequencing
  - 5.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.3. PCR
  - 5.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.4. Epigenetics
  - 5.4.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.5. Genotyping
  - 5.4.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.6. RCA/MDA
  - 5.4.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.7. RNA Therapeutics
  - 5.4.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.8. Transcriptomics
  - 5.4.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.9. Proteomics
  - 5.4.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.10. Liquid Biopsy
  - 5.4.10.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4.11. Other Applications
  - 5.4.11.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Molecular Biology Enzymes, Reagents And Kits Market: End use Estimates & Trend Analysis

6.1. End use Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Global Molecular Biology Enzymes, Reagents And Kits Market by End use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 6.4.1. Pharma & Biotech
  - 6.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4.2. Academic & Research
  - 6.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4.3. Hospital & Diagnostics
  - 6.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4.4. Other
  - 6.4.4.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
- 7.4.1. Illumina, Inc.
  - 7.4.1.1. Participant's Overview
  - 7.4.1.2. Financial Performance
  - 7.4.1.3. Product Benchmarking
  - 7.4.1.4. Recent Developments/Strategic Initiatives
- 7.4.2. Thermo Fisher Scientific, Inc.
  - 7.4.2.1. Participant's Overview
  - 7.4.2.2. Financial Performance
  - 7.4.2.3. Product Benchmarking
  - 7.4.2.4. Recent Developments/Strategic Initiatives
- 7.4.3. Agilent Technologies, Inc.
  - 7.4.3.1. Participant's Overview
  - 7.4.3.2. Financial Performance
  - 7.4.3.3. Product Benchmarking
  - 7.4.3.4. Recent Developments/Strategic Initiatives
- 7.4.4. QIAGEN
  - 7.4.4.1. Participant's Overview
  - 7.4.4.2. Financial Performance
  - 7.4.4.3. Product Benchmarking
  - 7.4.4.4. Recent Developments/Strategic Initiatives
- 7.4.5. Promega Corporation
  - 7.4.5.1. Participant's Overview
  - 7.4.5.2. Financial Performance
  - 7.4.5.3. Product Benchmarking
  - 7.4.5.4. Recent Developments/Strategic Initiatives
- 7.4.6. New England Biolabs
  - 7.4.6.1. Participant's Overview
  - 7.4.6.2. Financial Performance
  - 7.4.6.3. Product Benchmarking
  - 7.4.6.4. Recent Developments/Strategic Initiatives
- 7.4.7. Merck KGaA
  - 7.4.7.1. Participant's Overview
  - 7.4.7.2. Financial Performance
  - 7.4.7.3. Product Benchmarking
  - 7.4.7.4. Recent Developments/Strategic Initiatives
- 7.4.8. F. Hoffmann-La Roche Ltd.
  - 7.4.8.1. Participant's Overview
  - 7.4.8.2. Financial Performance
  - 7.4.8.3. Product Benchmarking
  - 7.4.8.4. Recent Developments/Strategic Initiatives
- 7.4.9. Bio-Rad Laboratories, Inc.
  - 7.4.9.1. Participant's Overview
  - 7.4.9.2. Financial Performance
  - 7.4.9.3. Product Benchmarking
  - 7.4.9.4. Recent Developments/Strategic Initiatives
- 7.4.10. Takara Bio, Inc.
  - 7.4.10.1. Participant's Overview
  - 7.4.10.2. Financial Performance
  - 7.4.10.3. Product Benchmarking
  - 7.4.10.4. Recent Developments/Strategic Initiatives
- 7.4.11. LGC Limited
  - 7.4.11.1. Participant's Overview
  - 7.4.11.2. Financial Performance
  - 7.4.11.3. Product Benchmarking
  - 7.4.11.4. Recent Developments/Strategic Initiatives